Literature DB >> 7900083

Expression of platelet membrane glycoprotein V in human megakaryocytes and megakaryocytic cell lines: a study using a novel monoclonal antibody against GPV.

T Takafuta1, K Fujimura, H Kawano, M Noda, T Fujimoto, K Oda, T Shimomura, A Kuramoto.   

Abstract

Glycoprotein V (GPV) is a platelet membrane protein with a molecular weight of 82 kD, and one of the leucine rich glycoproteins (LRG). By reverse transcription-polymerase chain reaction (RT-PCR), GPV cDNA was amplified from mRNA of platelets and megakaryocytic cell lines. However, since there are few reports indicating whether GPV protein is expressed in megakaryocytes as a lineage and maturation specific protein, we studied the GPV expression at the protein level by using a novel monoclonal antibody (1D9) recognizing GPV. Flow cytometric and immunohistochemical analysis indicated that GPV was detected on the surface and in the cytoplasm of only the megakaryocytes in bone marrow aspirates. In a megakaryocytic cell line UT-7, GPV antigen increased after treatment with phorbol-12-myristate-13-acetate (PMA). These data indicate that only megakaryocytes specifically express the GPV protein among hematopoietic cells and that the expression of GPV increases with differentiation of the megakaryocyte as GPIb-IX complex.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7900083

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  2 in total

1.  Development of a Bioinformatics Framework for Identification and Validation of Genomic Biomarkers and Key Immunopathology Processes and Controllers in Infectious and Non-infectious Severe Inflammatory Response Syndrome.

Authors:  Dong Ling Tong; Karen E Kempsell; Tamas Szakmany; Graham Ball
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

2.  Involvement of autophagy in diosgenin‑induced megakaryocyte differentiation in human erythroleukemia cells.

Authors:  Bertrand Liagre; David Yannick Leger; Dima Diab; Aline Pinon; Catherine Ouk; Rouba Hage-Sleiman; Mona Diab-Assaf
Journal:  Mol Med Rep       Date:  2021-08-30       Impact factor: 2.952

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.